CA2442168C - N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity - Google Patents

N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity Download PDF

Info

Publication number
CA2442168C
CA2442168C CA2442168A CA2442168A CA2442168C CA 2442168 C CA2442168 C CA 2442168C CA 2442168 A CA2442168 A CA 2442168A CA 2442168 A CA2442168 A CA 2442168A CA 2442168 C CA2442168 C CA 2442168C
Authority
CA
Canada
Prior art keywords
oxidative
acetylcysteine
acetaminophen
therapeutic
produces
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA2442168A
Other languages
English (en)
French (fr)
Other versions
CA2442168A1 (en
Inventor
Leonard A. Herzenberg
Stephen C. De Rosa
James Andrus
Leonore A. Herzenberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26960383&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2442168(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Publication of CA2442168A1 publication Critical patent/CA2442168A1/en
Application granted granted Critical
Publication of CA2442168C publication Critical patent/CA2442168C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2442168A 2001-03-30 2002-03-28 N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity Expired - Lifetime CA2442168C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US28060001P 2001-03-30 2001-03-30
US60/280,600 2001-03-30
US09/833,228 US6566401B2 (en) 2001-03-30 2001-04-11 N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity
US09/833,228 2001-04-11
PCT/US2002/009442 WO2002078627A2 (en) 2001-03-30 2002-03-28 N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity

Publications (2)

Publication Number Publication Date
CA2442168A1 CA2442168A1 (en) 2002-10-10
CA2442168C true CA2442168C (en) 2012-05-29

Family

ID=26960383

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2442168A Expired - Lifetime CA2442168C (en) 2001-03-30 2002-03-28 N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity

Country Status (13)

Country Link
US (2) US6566401B2 (https=)
EP (1) EP1379232B1 (https=)
JP (3) JP2005508840A (https=)
CN (1) CN100464743C (https=)
AU (1) AU2002255942B2 (https=)
BR (1) BR0208563A (https=)
CA (1) CA2442168C (https=)
ES (1) ES2550094T3 (https=)
IL (2) IL158181A0 (https=)
MX (1) MXPA03008904A (https=)
NZ (1) NZ528478A (https=)
RU (1) RU2291689C2 (https=)
WO (1) WO2002078627A2 (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7662863B2 (en) * 2003-06-09 2010-02-16 Alan Andrews Therapeutic agent for the use in reducing alcohol intoxication and reducing or eliminating the negative side effects associated with alcohol ingestion
US8778979B2 (en) 2005-04-05 2014-07-15 Yale University Glutamate agents in the treatment of mental disorders
US8993627B2 (en) 2005-04-21 2015-03-31 Sentient Lifesciences, Inc. N-acetylcysteine amide (NAC amide) for the treatment of diseases and conditions associated with oxidative stress
US8148356B2 (en) 2005-08-24 2012-04-03 Cumberland Pharmaceuticals, Inc. Acetylcysteine composition and uses therefor
RU2302236C2 (ru) * 2005-09-09 2007-07-10 Государственное учреждение научно-исследовательский институт Гриппа Российской академии медицинских наук (ГУ НИИ Гриппа РАМН) Средство, обладающее антигипоксической и цитопротекторной активностями, используемое для снижения токсичности ремантадина при лечении гриппозной инфекции
US20070098790A1 (en) * 2005-10-31 2007-05-03 David Jiang Nutritional supplement for the enhancement of the health of the liver
US20080139654A1 (en) * 2006-12-09 2008-06-12 Eric Mott Soderling Acetaminophen compositions having minimized side effects including reduced hepatotoxicity
EP2291182A1 (en) * 2008-05-13 2011-03-09 Genmedica Therapeutics SL Salicylate conjugates useful for treating metabolic disorders
CA2755069A1 (en) * 2009-03-16 2010-09-23 Genmedica Therapeutics Sl Anti-inflammatory and antioxidant conjugates useful for treating metabolic disorders
CN102421424A (zh) * 2009-03-16 2012-04-18 根梅迪卡治疗公司 用于治疗代谢性疾病的组合疗法
WO2010132864A1 (en) * 2009-05-15 2010-11-18 Intermune, Inc. Methods of treating hiv patients with anti-fibrotics
US20120122787A1 (en) * 2009-07-10 2012-05-17 Rong Li Methods for treating polycystic kidney disease (pkd) or other cyst forming diseases
EP2453743B1 (en) 2009-07-15 2017-04-12 The Board of Trustees of The Leland Stanford Junior University N-acetyl cysteine compositions and their use in improving the therapeutic efficacy of acetaminophen
DE102011006425A1 (de) 2010-03-31 2011-10-06 Awd.Pharma Gmbh & Co. Kg Pharmazeutische Zubereitung und deren Verwendung
US8466197B2 (en) 2010-12-14 2013-06-18 Genmedica Therapeutics Sl Thiocarbonates as anti-inflammatory and antioxidant compounds useful for treating metabolic disorders
US20140135396A1 (en) * 2011-07-05 2014-05-15 Beth Israel Deaconess Medical Center, Inc. Treatment of Acetaminophen-Induced Liver Damage by the Administration of Modulators of Nitric Oxide
US8747894B2 (en) 2012-05-08 2014-06-10 Alpex Pharma S.A. Effervescent compositions containing N-acetylcysteine
EP2854798A4 (en) 2012-05-24 2016-05-11 Mograbi Josef COMPOSITIONS WITH ISOSILYBIN B FOR THE TREATMENT AND PREVENTION OF ACTIVE-INDUCED TOXICITY
PL3639828T3 (pl) 2013-12-24 2022-05-02 Virginia Commonwealth University Zastosowanie utlenowanych siarczanów cholesterolu (ocs) w leczeniu ostrej niewydolności wątroby
WO2016123223A1 (en) * 2015-01-27 2016-08-04 Florengale, Llc Healing topical composition
HK1249035A1 (zh) * 2015-05-27 2018-10-26 University Of Pittsburgh - Of The Commonwealth System Of Higher Education 降低成像後胰腺炎风险的组合物和方法
BR112017025499A2 (pt) 2015-05-28 2018-08-07 Baylor College Medicine benefícios da suplementação com n-acetil cisteína e glicina para melhorar os níveis de glutationa
EP3402475B1 (en) * 2016-01-11 2021-10-20 Egetis Therapeutics AB Methods and formulations for treatment of and/or protection against acute liver failure and other hepatotoxic conditions
CA3012837A1 (en) 2016-02-04 2017-08-10 Czap Research And Development, Llc Controlled-release and stratified cyclodextrin inclusion complex vehicles
DK3554491T3 (en) 2016-12-15 2023-05-15 Zambon Spa N-acetylcystein til anvendelse som antibakterielt middel
US11040007B2 (en) * 2017-01-24 2021-06-22 Woosung Pharmaceutical Co., Ltd. Injection composition containing acetaminophen
EP3901620A4 (en) * 2018-12-21 2022-02-16 FUJIFILM Corporation PHOTOTOXICITY OR PHOTOALLERGY MEASUREMENT PROCEDURE AND REAGENT FOR USE IN THAT MEASUREMENT
US11590090B2 (en) 2019-09-14 2023-02-28 Anzen Pharmaceuticals, LLC Acetaminophen formulation with protection against toxic effects of overdose
GB2588172B (en) * 2019-10-11 2023-05-24 Blackhawk Partners Ltd A pharmaceutical composition comprising cannabinoid
CN113288890B (zh) * 2021-06-21 2022-02-22 南方医科大学南方医院 N-乙酰-l-半胱氨酸在制备预防和/或治疗运动损伤的药物中的应用
WO2023010088A1 (en) 2021-07-28 2023-02-02 Pono Lifestyle Colorado, Llc Nutraceutical formulations to prevent, treat, and inhibit excess cytokines, sars-cov-2 spike proteins, and mrna vaccine spike proteins
EP4238559A1 (en) 2022-03-04 2023-09-06 Centre Hospitalier Universitaire de Caen Normandie Combinations of acetaminophen and n-acetyl cysteine for the treatment of pain and fever

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US547457A (en) * 1895-10-08 Trolley-track
IT1141406B (it) * 1980-04-01 1986-10-01 Dob Far Spa Sali della cefapirina con aminoacidi
FR2519988B1 (fr) * 1982-01-20 1985-06-14 Refarmed Sa Derives thioliques de l'erythromycine a activite therapeutique, procede de preparation et produits pharmaceutiques dans lesquels ils apparaissent
DE3616923A1 (de) 1986-05-20 1987-11-26 Nattermann A & Cie Neue pharmazeutische verwendung von 2-phenyl-1,2-benzisoselenazol-3(2h)-on
CA1339256C (en) * 1989-01-26 1997-08-12 Wulf Droge Treatment of diseases associated with hiv-infections
IT1248995B (it) * 1990-06-26 1995-02-11 Italfarmaco Spa Composizioni farmaceutiche a base di sali ferrosi
US5474757A (en) * 1992-10-16 1995-12-12 Rutgers University Prevention of acetaminophen overdose toxicity with organosulfur compounds
US5762922A (en) * 1994-01-31 1998-06-09 Ludwig Institute For Cancer Research Antioxidants and intracellular gluthathione raising agents for therapeutic treatments
US5475757A (en) * 1994-06-07 1995-12-12 At&T Corp. Secure data transmission method
WO1996019489A1 (en) * 1994-12-19 1996-06-27 Russinsky Limited Compounds
US5750493A (en) * 1995-08-30 1998-05-12 Raymond F. Schinazi Method to improve the biological and antiviral activity of protease inhibitors
FR2744917B1 (fr) 1996-02-16 1998-04-10 Kouchner Gerard Composition therapeutique a base d'acetaminophene
US5837729A (en) * 1996-04-26 1998-11-17 Metatron, Inc. Methods for treating and preventing HIV infection using acetaminophen and derivatives thereof
US5962421A (en) * 1996-05-16 1999-10-05 Zambon, S.A. Pharmacological association between N-acetylcysteine and levulose for preventing cellular death and related diseases
CA2294247C (en) * 1997-07-01 2004-10-26 Atherogenics, Inc. Antioxidant enhancement of therapy for hyperproliferative conditions
CA2355859A1 (en) * 1999-01-04 2000-07-13 Ml Laboratories Plc Gene therapy-1
IT1312086B1 (it) * 1999-04-21 2002-04-04 Zambon Spa Uso della nac per la preparazione di un medicamento adatto allasomministrazione endovenosa per la prevenzione dello stress
DE10112325A1 (de) 2001-03-13 2002-10-02 Fresenius Kabi De Gmbh Lagerstabile Fertiginfusionslösungen des Paracetamols

Also Published As

Publication number Publication date
US7723389B2 (en) 2010-05-25
JP2015078185A (ja) 2015-04-23
WO2002078627A3 (en) 2003-09-18
CA2442168A1 (en) 2002-10-10
CN1507350A (zh) 2004-06-23
NZ528478A (en) 2007-08-31
RU2003131876A (ru) 2005-04-10
AU2002255942B2 (en) 2007-07-05
IL158181A0 (en) 2004-03-28
RU2291689C2 (ru) 2007-01-20
US6566401B2 (en) 2003-05-20
CN100464743C (zh) 2009-03-04
JP2011225610A (ja) 2011-11-10
WO2002078627A2 (en) 2002-10-10
IL158181A (en) 2012-04-30
US20020142991A1 (en) 2002-10-03
EP1379232B1 (en) 2015-07-29
JP2005508840A (ja) 2005-04-07
EP1379232A4 (en) 2008-04-23
ES2550094T3 (es) 2015-11-04
US20030069311A1 (en) 2003-04-10
BR0208563A (pt) 2006-02-21
EP1379232A2 (en) 2004-01-14
MXPA03008904A (es) 2005-03-07

Similar Documents

Publication Publication Date Title
CA2442168C (en) N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity
AU2002255942A1 (en) N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity
Mitchell et al. Molecular basis for several drug-induced nephropathies
US5474757A (en) Prevention of acetaminophen overdose toxicity with organosulfur compounds
Patrick N-acetylcysteine, Alpha-Lipoic Acid, L-Glutamine, and L-Carnitine
US20050070607A1 (en) N-acetylcysteine compositions and methods for the treatment and prevention of cysteine/glutathione deficiency in diseases and conditions
EP2453743B1 (en) N-acetyl cysteine compositions and their use in improving the therapeutic efficacy of acetaminophen
US5248697A (en) Enhancement of glutathione levels with glutamine
EP2723448A1 (en) Compositions and methods for treatment of chronic fatigue
Beltrán-Olazábal et al. Management of acetaminophen toxicity, a review
US6048540A (en) Acetamenophen composition with reduced liver toxicity
ZA200307559B (en) N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity.
US6441011B1 (en) Combined preparation consisting of 2-methylthiazolidine-2,4-dicarboxylic acid and paracetamol
JPH0314812B2 (https=)
RU2096034C1 (ru) Фармацевтическая композиция, индуцирующая биосинтез глутатиона, активность глутатионтрансферазы и оказывающая антитоксическое, радиопротекторное и антигипоксическое действие, и способы лечения, профилактики и защиты с ее использованием
US20050182136A1 (en) N-acetylcysteine compositions and methods for the treatment and prevention of endothelial dysfunction
Hodgson et al. Acute arsenic exposure secondary to deliberate self-poisoning with sheep dip
US20150202181A1 (en) Method of and compounds for the reduction of alcoholic hangover
BR112021014509A2 (pt) Compostos de beta-lactama ou sais dos mesmos para uso na prevenção de ação prolongada ou tratamento de um transtorno de metabolismo de glicose
JPS6354690B2 (https=)
Andrus et al. Cysteine/glutathione deficiency: a significant and treatable corollary of disease (a systematic literature review)
HK1173336A (en) N-acetyl cysteine compositions and methods to improved the therapeutic efficacy of acetaminophen
JPS6232169B2 (https=)

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20220328